Her2/neu expression in urothelial dysplasia, carcinoma in situ, and superficial urothelial carcinoma and its value in assessing the response to BCG therapy

Conclusion: Evaluation of Her2/neu overexpression as well as histopathologic features may help in differentiating high-grade urothelial dysplasia from urothelial carcinoma, both carcinoma in situ and superficially invasive urothelial carcinomas of the urinary bladder (Ta–T1). Her2/neu overexpression increased with increase in tumor grade. Thus the assessment of Her2/neu status can be helpful in identifying patients at high risk of disease progression. The reduction in expression of Her2/neu after BCG adjuvant therapy in superficial urothelial carcinoma cases supports the role of BCG as a targeted therapy for these tumors.
Source: Egyptian Journal of Pathology - Category: Pathology Tags: Original Articles Source Type: research